Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2008 1
2009 3
2013 1
2015 1
2018 2
2019 2
2020 10
2021 7
2022 2
2023 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
[Umifenovir and coronavirus infections: a review of research results and clinical practice].
Leneva IA, Pshenichnaya NY, Bulgakova VA. Leneva IA, et al. Ter Arkh. 2020 Dec 26;92(11):91-97. doi: 10.26442/00403660.2020.11.000713. Ter Arkh. 2020. PMID: 33720612 Review. Russian.
A meta-analysis of clinical trials results was performed. Umifenovir is antiviral agent, it belongs to fusion inhibitors, interacts with SARS-CoV-2 spike protein. ...Preclinical studies in vitro and on animals show umifenovir activity against a number of coronavirus …
A meta-analysis of clinical trials results was performed. Umifenovir is antiviral agent, it belongs to fusion inhibitors, interacts w …
Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Huang D, et al. J Med Virol. 2021 Jan;93(1):481-490. doi: 10.1002/jmv.26256. Epub 2020 Jul 14. J Med Virol. 2021. PMID: 32617989 Free PMC article.
Additionally, umifenovir was safe in COVID-19 patients (RR for incidence of adverse events: 1.29; 95% CI: 0.57 to 2.92). ...There is no evidence to support the use of umifenovir for improving patient-important outcomes in patients with COVID-19....
Additionally, umifenovir was safe in COVID-19 patients (RR for incidence of adverse events: 1.29; 95% CI: 0.57 to 2.92). ...There is …
Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.
Amani B, Amani B, Zareei S, Zareei M. Amani B, et al. Immun Inflamm Dis. 2021 Dec;9(4):1197-1208. doi: 10.1002/iid3.502. Epub 2021 Aug 4. Immun Inflamm Dis. 2021. PMID: 34347937 Free PMC article.
OBJECTIVE: To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID-19 treatment. METHODS: A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. ...
OBJECTIVE: To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID-19 treatment. METHODS: A liter …
Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study.
Leneva IA, Falynskova IN, Makhmudova NR, Poromov AA, Yatsyshina SB, Maleev VV. Leneva IA, et al. J Med Virol. 2019 Apr;91(4):588-597. doi: 10.1002/jmv.25358. Epub 2018 Dec 2. J Med Virol. 2019. PMID: 30431664 Clinical Trial.
No molecular markers of umifenovir resistance were identified in influenza viruses isolate d from patients at 3, 5, and 7 days after initiation of therapy. None of the viruses isolated before and during umifenovir therapy displayed reduced susceptibility to neuramin …
No molecular markers of umifenovir resistance were identified in influenza viruses isolate d from patients at 3, 5, and 7 days after …
Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR).
Pshenichnaya NY, Bulgakova VA, Lvov NI, Poromov AA, Selkova EP, Grekova AI, Shestakova IV, Maleev VV, Leneva IA. Pshenichnaya NY, et al. Ter Arkh. 2019 Mar 30;91(3):56-63. doi: 10.26442/00403660.2019.03.000127. Ter Arkh. 2019. PMID: 31094461 Clinical Trial.
Duration of intoxication was reduced with umifenovir compared to placebo, amounted to 77.76 and 88.91 hours, respectively, p=0.013. ...Umifenovir and placebo were well tolerated. A total of 42 cases of adverse events were registered in 11 patients in the treatment g …
Duration of intoxication was reduced with umifenovir compared to placebo, amounted to 77.76 and 88.91 hours, respectively, p=0.013. . …
Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis.
Gao Y, Zhao Y, Liu M, Luo S, Chen Y, Chen X, Zheng Q, Xu J, Shen Y, Zhao W, Li Z, Huang S, Huang J, Tian J, Guyatt G, Hao Q. Gao Y, et al. JAMA Intern Med. 2025 Mar 1;185(3):293-301. doi: 10.1001/jamainternmed.2024.7193. JAMA Intern Med. 2025. PMID: 39804622
For time to alleviation of symptoms, baloxavir probably reduced symptom duration (mean difference [MD], -1.02 days; 95% CI, -1.41 to -0.63; moderate certainty); umifenovir may have reduced symptom duration (MD, -1.10 days; 95% CI, -1.57 to -0.63; low certainty); oseltamivi …
For time to alleviation of symptoms, baloxavir probably reduced symptom duration (mean difference [MD], -1.02 days; 95% CI, -1.41 to -0.63; …
Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients.
Ramachandran R, Bhosale V, Reddy H, Atam V, Faridi M, Fatima J, Shukla V, Khan ZA, Khan H, Singh V, Negi MPS, Srivastava M, Srivastava AK, Tripathi CB, Ghosh N, Majumdar N, Tripathi RK, Rath SK, Mishra PR, Sharma S, Kundu TK. Ramachandran R, et al. Int J Infect Dis. 2022 Feb;115:62-69. doi: 10.1016/j.ijid.2021.11.025. Epub 2021 Nov 19. Int J Infect Dis. 2022. PMID: 34801738 Free PMC article. Clinical Trial.
OBJECTIVE: To test efficacy, safety and tolerability of Umifenovir in non-severe COVID-19 adult patients. METHODS: We carried out randomized, double-blind, placebo-controlled, multicenter, phase III trials involving adult (18-75 years), non-severe COVID19 patients, randomi …
OBJECTIVE: To test efficacy, safety and tolerability of Umifenovir in non-severe COVID-19 adult patients. METHODS: We carried out ran …
Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
Ibrahim S, Siemieniuk RAC, Oliveros MJ, Islam N, Díaz Martinez JP, Izcovich A, Qasim A, Zhao Y, Zaror C, Yao L, Wang Y, Vandvik PO, Roldan Y, Rochwerg B, Rada G, Prasad M, Pardo-Hernandez H, Mustafa RA, Fashami FM, Miroshnychenko A, McLeod SL, Mansilla C, Lamontagne F, Khosravirad A, Honarmand K, Ghadimi M, Gao Y, Foroutan F, Devji T, Couban R, Chu DK, Chowdhury SR, Chang Y, Bravo-Soto G, Bosio C, Biscay D, Bhogal G, Azab M, Agoritsas T, Agarwal A, Guyatt GH, Brignardello-Petersen R. Ibrahim S, et al. BMJ. 2025 May 29;389:e081165. doi: 10.1136/bmj-2024-081165. BMJ. 2025. PMID: 40441732 Free PMC article.
Compared with standard care, azithromycin probably reduces time to symptom resolution (mean difference 4 days fewer (5 fewer to 3 fewer), moderate certainty) and systemic corticosteroids, favipiravir, molnupiravir, and umifenovir probably also reduce duration of symptoms ( …
Compared with standard care, azithromycin probably reduces time to symptom resolution (mean difference 4 days fewer (5 fewer to 3 fewer), mo …
[Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR].
Kiselev OI, Maleev VV, Deeva EG, Leneva IA, Selkova EP, Osipova EA, Obukhov AA, Nadorov SA, Kulikova EV. Kiselev OI, et al. Ter Arkh. 2015;87(1):88-96. doi: 10.17116/terarkh201587188-96. Ter Arkh. 2015. PMID: 25823275 Clinical Trial. Russian.
Umifenovir had influence on the time to resolution of all symptoms. All symptoms were resolved within the first 60 hours after therapy initiation in 23.8% patients with laboratory-confirmed influenza in the umifenovir group and it was 5.7 times greater compared to p …
Umifenovir had influence on the time to resolution of all symptoms. All symptoms were resolved within the first 60 hours after therap …
28 results